[{"id":"fd493fb6-1fae-4488-8af2-eb5f7acb16dc","acronym":"Debio 1562-201","url":"https://clinicaltrials.gov/study/NCT02564744","created_at":"2024-05-25T04:22:50.646Z","updated_at":"2024-07-02T16:34:27.014Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL","source_id_and_acronym":"NCT02564744 - Debio 1562-201","lead_sponsor":"Debiopharm International SA","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • naratuximab emtansine (DEBIO 1562)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 06/05/2016","start_date":" 06/05/2016","primary_txt":" Primary completion: 01/13/2021","primary_completion_date":" 01/13/2021","study_txt":" Completion: 06/25/2021","study_completion_date":" 06/25/2021","last_update_posted":"2024-06-12"}]